Partner, National Sector Leader, Healthcare , KPMG (US)
Thriving in a converging environment: learn how KPMG can help pharmaceutical, medical device and diagnostic companies turn disruption into opportunity.
Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.
Proposed safe harbor changes open for comment
Consider applying for the voluntary initiative
Rising to the data challenge
Reinvent innovation and become an R&D front-runner by 2030
2019 Health Care & Life Sciences Investment Outlook
Unlocking value for life sciences organizations
This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.
KPMG/RAPS survey illustrates the ground medical device companies still have to cover
2018 Program benchmark report
Identifying opportunities for life sciences manufacturers.
Innovation in the life sciences finance function
As new entrants and cross-sector models abound, which direction should healthcare organizations turn?
Blockchain could be a key to interoperability and privacy
As demand for pharmaceutical cost containment intensifies, novel drug-pricing approaches are critical
New standard. New challenges.
Making a power play to avoid the commodity trap
Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.
Navigating a transforming life sciences landscape
GDPR in Life Sciences Reference Card
A focused approach to winning in 2030
Work together to strike a balance between strong cyber-security measures and the ability to treat patients
Breakthrough drugs and devices present greater opportunities…and risks
Medical device "Frameworks and standards
A closer look
Register to receive timely insights
Meet our team